XCUR · Exicure, Inc.
$1.29
-0.12 (-8.51%)
At close · Aug 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that, given the Company's current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. Additional financing will be needed to fund ongoing operations, support of GPCR USA's operations, and exploration of strategic alternatives and pursuing any alternatives that management identifies. Management's plan to alleviate this substantial doubt include pursuing additional equity and/or debt financings, strategic transactions, potential business combination opportunities and other sources of capital. However, there can be no assurance that such plans will be successful.”View the 10-Q filed Aug 14, 2026
Market Cap
$8.44M
Shares
6.55M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$4.95M
+49%
FY2025
Operating Margin
-2446.4%
FY2024
Diluted EPS
-$0.79
+83.4%
FY2025
Operating Cash Flow
-$8.56M
-194%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $500K | $0 | $28.83M | -$483K | $16.61M | $1.3M | $118K | $9.72M | $1.04M | |
| $2.03M | $3.29M | $0 | $1.42M | $19.77M | $48.98M | $32.09M | $19.34M | $14.12M | $13.08M | $13.66M | |
| $5.28M | $6.83M | $5.45M | $11.72M | $10.89M | $13.09M | $9.96M | $8.57M | $7.82M | $7.05M | $3.54M | |
| $199K | $242K | $28K | $634K | $1.16M | $1.12M | $766K | $392K | $358K | $232K | $180K | |
| — | — | — | — | $488K | — | — | — | — | — | — | |
| $7.34M | $4.23M | $12.73M | $15M | $30.66M | $62.07M | $42.05M | $27.91M | $21.94M | $20.13M | $17.2M | |
| -$7.34M | -$4.23M | -$12.23M | -$15M | -$1.83M | -$62.55M | -$25.44M | -$26.62M | -$21.82M | -$10.41M | -$16.16M | |
| — | — | -2446.4% | — | -6.35% | — | -153.11% | -2053.78% | -18490.68% | -107.08% | -1560.04% | |
| -$7.14M | -$3.99M | -$12.2M | -$14.36M | -$668K | -$61.43M | -$24.67M | -$26.23M | -$21.46M | -$10.18M | -$15.98M | |
| — | $1000 | $18K | $0 | $595K | $1.69M | $573K | $786K | $672K | $795K | $724K | |
| $31K | $29K | $8000 | $32K | $15K | $141K | $972K | $178K | — | — | — | |
| -$1.58M | -$1.35M | $2.54M | -$1.92M | -$542K | -$1.55M | $768K | $314K | -$594K | -$604K | -$779K | |
| -$8.92M | -$5.58M | -$9.69M | -$16.91M | -$2.37M | -$64.1M | -$24.67M | -$26.3M | — | -$12.04M | -$16.94M | |
| -$634K | -$634K | $8000 | $0 | $209K | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$8.28M | -$4.95M | -$9.7M | -$16.91M | -$2.58M | -$64.1M | -$24.67M | -$26.3M | -$22.41M | -$11.01M | -$16.94M | |
| — | — | -1940.2% | — | -8.96% | — | -148.49% | -2029.55% | -18994.07% | -113.29% | -1635.23% | |
| — | -$4.95M | -$9.7M | -$16.91M | -$2.58M | -$64.1M | -$24.67M | — | — | — | — | |
| — | -$4.95M | -$9.7M | -$16.91M | -$2.58M | -$64.19M | -$24.56M | -$26.33M | -$22.41M | — | — | |
| USD/shares | -$1.34 | -$0.79 | -$4.75 | -$10.55 | -$2.80 | -$108.50 | -$42.00 | — | — | — | — |
| USD/shares | -$1.34 | -$0.79 | -$4.75 | -$10.55 | -$2.80 | -$108.50 | -$42.00 | — | — | — | — |
| shares | — | 6.3M | 2.04M | 1.6M | 923.89K | 590.78K | 581.36K | 384.48K | 274.59K | 67.46K | 756.12 |
| shares | — | 6.3M | 2.04M | 1.6M | 923.89K | 590.78K | 581.36K | 384.48K | 274.59K | 67.46K | 756.12 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.62×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.89×
Peer medians compare against the 181 similar-size Biotechnology companies (of 508 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Biotechnology Segment | $0 | $500,000 | $0 |